About this Research Topic
Frontiers in Oncology is pleased to introduce the “Drug Delivery” series of Research Topics, each exploring the development, validation, optimization and integration of novel drug delivery methods for the treatment of cancer. Treatment strategies for cancer have traditionally been composed of combinations of radiotherapy, chemotherapy and surgical approaches; however, these have limitations including lack of efficacy in later stage disease, eventual treatment failure due to drug resistance, and health-related adverse events resulting from non-specificity and cytotoxicity.
Recent advances in our understanding of carcinogenesis and tumorigenesis are now enabling the identification and development of novel drug delivery systems (DDSs), which may enable the delivery of existing drugs in a more targeted manner. Key novel drug delivery systems under investigation include nanotechnologies, siRNA systems and viral vectors, in addition to many emerging systems.
Lipid-based DDSs include liposomes, lipid nanoparticles (NPs) and emulsions. Advantages of lipid-based NPs DDSs include simple formulation, self-assembly, biocompatibility, high bioavailability and the ability to carry large payloads, in addition to having physicochemical properties which can be controlled to modulate their biological properties, whilst disadvantages include low encapsulation efficiency. Lipid-based NPs are currently FDA approved for the treatment of sarcoma, ovarian cancer, pancreatic cancer, multiple myeloma and some leukemias.
This Research Topic welcomes the submission of manuscripts advancing the use of DDS leveraging lipid-based NPs for the treatment of cancer.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Recent advances in our understanding of carcinogenesis and tumorigenesis are now enabling the identification and development of novel drug delivery systems (DDSs), which may enable the delivery of existing drugs in a more targeted manner. Key novel drug delivery systems under investigation include nanotechnologies, siRNA systems and viral vectors, in addition to many emerging systems.
Lipid-based DDSs include liposomes, lipid nanoparticles (NPs) and emulsions. Advantages of lipid-based NPs DDSs include simple formulation, self-assembly, biocompatibility, high bioavailability and the ability to carry large payloads, in addition to having physicochemical properties which can be controlled to modulate their biological properties, whilst disadvantages include low encapsulation efficiency. Lipid-based NPs are currently FDA approved for the treatment of sarcoma, ovarian cancer, pancreatic cancer, multiple myeloma and some leukemias.
This Research Topic welcomes the submission of manuscripts advancing the use of DDS leveraging lipid-based NPs for the treatment of cancer.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: drug delivery, oncology, cancer, lipid-based nanoparticles
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
